ArticleJournal of advanced pharmaceutical technology & research
Glycyrrhizic acid mitigates the risk of nicotine addiction and nicotine withdrawal: The modulation of kynurenine aminotransferase II.
Article in Journal of advanced pharmaceutical technology & research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nicotine, a key addictive compound in cigarettes, contributes to withdrawal symptoms that hinder smoking cessation success. Understanding the neurochemical basis of nicotine addiction and withdrawal is critical for developing effective therapies. This study aimed to investigate the effect of glycyrrhizic acid (GL) on nicotine addiction and nicotine withdrawal, with a focus on the kynurenine pathway and kynurenine aminotransferase 2 (KAT-II) mRNA expression. An experimental study using mouse models to evaluate the behavioral and molecular effects of GL in nicotine-induced addiction and withdrawal. In the addiction model, mice received intraperitoneal injections of NaCl (1.0 mL/kg), nicotine (0.5 mg/kg), or GL (5, 10, or 20 mg/kg), and addiction was evaluated using the conditioned place preference (CPP) test. In the withdrawal model, mice underwent spontaneous withdrawal after chronic nicotine exposure, with GL (10 or 20 mg/kg) administered twice daily. Cognitive performance was evaluated using the T-maze, whereas hippocampal KAT-2 mRNA levels were quantified by real-time polymerase chain reaction. Statistical analysis was performed using ANOVA. Nicotine markedly increased CPP scores, confirming its rewarding effect, whereas GL at all doses significantly reduced these scores. During withdrawal, GL improved cognitive deficits and downregulated the nicotine-induced upregulation of hippocampal KAT-2 mRNA expression. GL effectively reduces nicotine-induced reward and mitigates cognitive deficits during withdrawal, likely through inhibition of KAT-2 mRNA expression in the hippocampus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.